Compare Northrop Grumman Corporation (NOC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Revvity Inc — how do they compare? Northrop Grumman Corporation trades at $480.72 (market cap $68.83B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Northrop Grumman Corporation is far larger — about 4.1× Revvity Inc's market cap, and Northrop Grumman Corporation pays the higher dividend (2.04%). Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and Revvity Inc for 12 Days on average.
| NOC | RVTY | |
|---|---|---|
Market Cap | $68.83B | $16.98B |
Volume | 1,081,989 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $768.02 | $157.36 |
52-Week Low | $473.46 | $82.26 |
Typical Hold Time | 81 Days | 12 Days |
Enterprise Value | $82.81B | $19.30B |
Dividend Yield | 2.04% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $484.48, up 2.33% today, but technical indicators signal a bearish trend with the stock below key moving averages. Fundamentally, the company shows strength with a P/E of 15.4, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights a mixed environment, including a significant contract loss to Boeing but sustained demand from defense budgets and a record backlog supporting future revenue.
The outlook remains positive due to strong fundamentals and analyst consensus, with a price target of $600.62 implying substantial upside. Key risks include competitive pressures from recent contract losses and dependence on government spending, but the company's financial health and dividend payments provide stability for investors.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
